we will participate in the CPhI China 2014(shanghai), our booth number is E3A05

  • CPhI China 2014,ChemCD,booth number is E3A05

  

   


Our company will participate in the Fourteenth CPhI China exhibition

Time: 26 - 28 June 2014

Venue: SNIEC, Shanghai, China

Booth No.: E3A05

We will take our new  website chemcd and software products debut, welcome you visit exchanges and cooperation!


Brief Introduction

As one of the largest global industry scale, the highest level, the most influential"CPHL " series exhibition, 26-28 June 2014, "the Fourteenth CPhI China Exhibition" (CPhI & BioPh China 2014 ) will have a grand debut again.

"the Fourteenth CPhI China Exhibition" (CPhI & BioPh China 2014 ) will have a grand debut again.


"Fourteenth CPhI China Exhibition" (CPhI & BioPh China 2014) will jointly "2014 World Chinese Medicine Exhibition customized services contract" (ICSE China 2014), "Ninth World pharmaceutical machinery, packaging equipment and materials China Exhibition "(P-MEC & InnoPack China 2014) and the" 2014 World biochemical, analytical instruments and laboratory equipment China Exhibition "(LABWorld China 2014), together constitute the global pharmaceutical business large industrial platforms, from pharmaceutical raw materials, contract customized for professionals , biopharmaceutical, pharmaceutical machinery, packaging materials to the laboratory instrument integration solutions.

 

Exhibition Introduction

This year Shanghai CPhI exhibition hall is divided into seven categories, New addition W3 Preparation exhibition hall, The other six respectively:


      Pharmaceutical raw materials        Biopharmaceutical

      Customized contract                                Natural extracts

        Pharmaceutical excipients                   Intermediates and fine chemicals




This link:  http://www.chemcd.com/news/46.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

This link:http://www.chemcd.com/news/46.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.